27 equity mutual funds offer over 25% CAGR in both 3 and 5 years. Have you added any to your portfolio?

Live Events
Around 27 equity mutual funds have offered over 25% CAGR in both the last three and five years. There were around 199 equity mutual funds that completed five years of existence in the market.Among these 27 schemes, the maximum schemes were from HDFC Mutual Fund. There were around five schemes from the fund house, followed by three each from Invesco Mutual Fund, Motilal Oswal Mutual Fund, and Nippon India Mutual Fund. Two schemes each from Bandhan Mutual Fund, Franklin Templeton Mutual Fund, and JM Mutual Fund. Seven other fund houses had one scheme each.Also Read | Over 260 debt mutual funds beat fixed deposits rate in 2 years. Should you switch? Bandhan Core Equity Fund and Bandhan Small Cap Fund offered over 25% CAGR in both the last three and five years. Edelweiss Mid Cap Fund offered 27.45% and 34.46% CAGR in the last three and five years, respectively.Mid and small cap funds from Franklin Templeton Mutual Fund - Franklin India Prima Fund and Franklin India Smaller Cos Fund - offered over 25% CAGR in the said horizons.Five schemes from HDFC Mutual Fund - HDFC ELSS Tax saver , HDFC Flexi Cap Fund, HDFC Focused 30 Fund, HDFC Mid-Cap Opportunities Fund, and HDFC Small Cap Fund - featured in the list of equity schemes that have offered over 25% CAGR in the said periods.HSBC Value Fund gave 25.59% and 31.32% CAGR in the last three and five years respectively. Three funds from Invesco Mutual Fund - Invesco India Large & Mid Cap Fund, Invesco India Midcap Fund, and Invesco India Smallcap Fund gained over 25% in the mentioned time periods.JM Flexicap Fund and JM Value Fund delivered over 25% CAGR in the same time periods. Mahindra Manulife Mid Cap Fund, the only scheme from Mahindra Manulife Mutual Fund, featured in the list.Three schemes - Motilal Oswal ELSS Tax Saver Fund, Motilal Oswal Large & Midcap Fund, and Motilal Oswal Midcap Fund - offered CAGR over 25% in the said time periods. Three schemes from Nippon India Mutual Fund were there in the list of schemes that gave over 25% CAGR in both the horizons. Quant Small Cap Fund offered 26.33% and 49.62% CAGR in the last three and five years, respectively. SBI Long Term Equity Fund, the oldest ELSS fund, offered 27.72% and 30.30% CAGR in the last three and five years, respectively.Also Read | HDFC Bank, Eternal among stocks bought and sold by SBI Mutual Fund in April Sundaram Mid Cap Fund offered 26.92% and 31.28% CAGR in the last three and five years, respectively.Among these 27 funds, Motilal Oswal Midcap Fund has offered the highest CAGR of around 31.93% in the last three years, whereas within the same universe, Quant Small Cap Fund has offered the highest CAGR of 49.62% in the last five years.We considered all equity mutual fund categories. We considered regular and growth options. We calculated the CAGR over the last three and five years.Note, the above exercise is not a recommendation. The exercise was done to find which equity schemes have offered over 25% CAGR in the last three and five years both. One should not make investment or redemption decisions based on the above exercise.One should always invest based on their risk appetite, investment horizon, and goals.(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Time of India

a day ago

• Time of India

Conman arrested for cheating investors in Erode district

COIMBATORE: A conman, who had been absconding for two years, was arrested by the economic offences wing police in Erode district on Friday in connection with a cheating case. The arrested man has been identified as Franklin, 50. Police said Naveenkumar, 38, of Edaiyankattuvalasu in Erode district started two companies -- Unique Exports and East Valley Agro Farms -- in 2017. He became the managing director of the two firms. Muthuselvan, an ex-serviceman from Ramanathapuram, was functioning as a partner. They promised a monthly return of Rs 18,000 as an incentive against a Rs 1 lakh deposit. Similarly, the firm offered various schemes to the investors. The general public, ex-servicemen and their families invested huge amounts in the two companies. The investors got incentives for two months. After that, the firms failed to give them incentives. Later, the companies were closed. Initially, the victims lodged a complaint with the Erode district crime branch police, who registered a case against Naveenkumar, Muthuselvan and a few others. The police arrested Naveenkumar while he was attempting to escape to Dubai from Chennai in 2023. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Confidence packed. Wrinkles left behind. Philips Garment Steamers Book Now Undo The case was transferred to the Erode economic offences wing police, who arrested Franklin from Nanjundapuram Perumal Kovil Street in Coimbatore city on Friday in connection with the case. More than 400 people have approached the police to get back their money.

Mint

3 days ago

• Mint

HDFC Mutual Fund raises stake in Glenmark Pharmaceuticals to 5.07%. Details here

HDFC Mutual Fund has increased its stake in Glenmark Pharmaceuticals, breaching the 5 percent ownership threshold, as per the company's regulatory filing on June 18, 2025. The move comes even as Glenmark disclosed recent regulatory scrutiny of its U.S. manufacturing facility by the United States Food and Drug Administration (USFDA). According to the filing, HDFC Mutual Fund purchased an additional 3.57 lakh equity shares of Glenmark Pharma, raising its holding by 0.13 percent. Prior to the transaction, the fund house held 1.39 crore shares, or 4.94 percent of the company. Post acquisition, its total shareholding stands at 1.43 crore shares, which translates to a 5.07 percent stake in the pharmaceutical major. The stake increase is seen as a mark of confidence in the company's fundamentals and long-term growth potential, especially amid recent regulatory developments. As per the March 2025 shareholding pattern, Glenmark's promoters continue to hold a dominant 46.65 percent stake in the company. In parallel with the stake hike, Glenmark Pharmaceuticals also updated the stock exchanges about a recent Good Manufacturing Practice (GMP) inspection conducted by the USFDA at its Monroe, North Carolina facility in the U.S. The inspection, which spanned from June 9 to June 17, 2025, culminated in the issuance of a Form 483 with five observations. The company was quick to clarify that the observations were procedural in nature and did not pertain to data integrity—an issue that often raises red flags in the pharmaceutical industry. In its exchange communication, Glenmark stated, 'The Company will work in close collaboration with the agency to address the observations and will respond to the USFDA within the stipulated timeline.' A Form 483 is typically issued when the FDA investigator identifies possible violations of the Food, Drug, and Cosmetic (FD&C) Act, but the absence of critical concerns such as data falsification is considered a relatively positive outcome. On the market front, Glenmark Pharma shares saw some volatility, falling by as much as 1.5 percent to touch a low of ₹ 1,634.55 on June 18. The stock is still around 11 percent below its 52-week high of ₹ 1,830.05, which it had touched in October 2025. However, it remains significantly above its 52-week low of ₹ 1,199.95, seen in June 2024. The recent price trajectory shows renewed investor interest, with the stock gaining 12.5 percent in June so far, following a 5.5 percent rise in May. This follows a choppy start to the year where the stock fell over 10 percent in April, surged 20.5 percent in March, and posted losses of 12 percent and 9.7 percent in February and January respectively. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.

Business Standard

6 days ago

• Business Standard

Motilal Oswal Mid Cap Fund: Spots moats before the drawbridge comes up

Early moves in resilient midcaps turn into long-haul winners premium Crisil Intelligence New Delhi Listen to This Article Motilal Oswal Mid Cap Fund, launched in February 2014, has ranked in the top 30 percentile of the midcap fund category in the Crisil Mutual Fund Ranking (CMFR) for three straight quarters through March 2025. The fund has been managed by Niket Shah since July 2020 and Ajay Khandelwal since October 2024. Its month-end assets under management rose to ₹26,028 crore in March 2025, up from ₹2,641 crore in March 2022. The fund aims to deliver long-term capital appreciation and steady income by investing in quality midcap companies with durable competitive advantages and clear growth visibility. The fund